Methylation status of a single CpG locus 3 bases upstream of TATA-box of receptor activator of nuclear factor-κB ligand (RANKL) gene promoter modulates cell- and tissue-specific RANKL expression and osteoclastogenesis

Molecular Endocrinology

Volumn 21, Issue 1, 2007, Pages 148-158

  Kitazawa, Riko ^a   Kitazawa, Sohei ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CALCITRIOL; OSTEOCLAST DIFFERENTIATION FACTOR; TATA BINDING PROTEIN; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SUBPOPULATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; GENE LOCUS; GENETIC TRANSCRIPTION; METHYLATION; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TATA BOX;

ANIMALS; AZACITIDINE; BONE MARROW CELLS; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION; MICE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; PROMOTER REGIONS (GENETICS); RANK LIGAND; RECEPTORS, CALCITRIOL; RNA, MESSENGER; STROMAL CELLS;

EID: 33845992511     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2006-0205     Document Type: Article

References (33)

1. Teitelbaum SL 1993 Bone remodeling and the osteoclast. J Bone Miner Res 8(Suppl 2):S523-S525
2. Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81
3. Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649
4. Lian JB, Stein GS 1992 Concepts of osteoblast growth and differentiation: basis for modulation of bone cell development and tissue formation. Crit Rev Oral Biol Med 3:269-305
5. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T 1988 Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122:1373-1382
6. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
9. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert LA 1997 homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179
10. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400
11. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT 1999 Localization of RANKL (receptor activator of NF-κB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25:525-534
12. Kitazawa S, Kitazawa R 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228-236
13. Mori H, Kitazawa R, Mizuki S, Nose M, Maeda S, Kitazawa S 2002 RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol 117:283-292
14. Pogoda P, Priemel M, Rueger JM, Amling M 2005 Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair. Osteoporos Int 16(Suppl 2):S18-S24
15. Kitazawa R, Kitazawa S, Maeda S 1999 Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta 1445:134-141
16. Liu J, Yang H, Liu W, Cao X, Feng X 2005 Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor-κB ligand gene in osteoblasts and bone marrow stromal cells. J Cell Biochem 96:716-727
17. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520
18. 3, and gp130 cytokines. J Bone Miner Res 19(Suppl 1):S28
19. Song F, Smith JF, Kimura MT, Morrow AD, Matsuyama T, Nagase H, Held WA 2005 Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression. Proc Natl Acad Sci USA 102:3336-3341
20. Mori K, Kitazawa R, Kondo T, Maeda S, Yamaguchi A, Kitazawa S 2006 Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. J Cell Biochem 93:1629-1644
21. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE, Carrington M, Trowsdale J, Lutz CT 2003 DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 197:245-255
22. 3 augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 290:650-655
23. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, 2005 Bird AP DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19:667-678
24. Tian K, Jurukovski V, Wang XP, Kaplan MH, Xu H 2005 Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells. Cancer Res 65:10024-10031
25. Jones PL, Veenstra GJ, Wada PA, Vermaak L, Kass SU, Landsberger N, Strouboulis J, Wolffe AP 1998 Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187-191
26. Aranda A, Pascual A 2001 Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304
27. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107
28. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323
29. Zhang Z, Deng C, Lu Q, Richardson D 2002 Age-dependent DNA methylation changes in the ITGAL (CD11a) promoter. Mech Ageing Dev 123:1257-1268
30. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP 1999 CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681-8686
31. Ogawa M, Nishikawa S, Ikuta K, Yamamura F, Naito M, Takahashi K, Nishikawa S 1998 B cell ontogeny in murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell progenitor develops first in the embryonal body rather than in the yolk sac. EMBO J 7:1337-1343
32. Dyer RB, Herzog NK 1995 Isolation of intact nuclei for nuclear extract preparation from a fragile B-lymphocyte cell line. Biotechniques 19:192-195
33. Kitazawa S, Kitazawa R, Maeda S 1999 Transcriptional regulation of rat cyclin D1 gene by CpG methylation status in promoter region. J Biol Chem 274:28787-28793